A TLR2 agonist is a more effective adjuvant for a chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors

Vaccine

Volumn 29, Issue 38, 2011, Pages 6641-6649

  Cheng, Chunmei ^a   Jain, Pooja ^a   Bettahi, Ilham ^a   Pal, Sukumar ^a   Tifrea, Delia ^a   de la Maza, Luis M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chlamydia trachomatis; Immunization; Mice; Pam2CSK4; Toll like receptors; Vaccine

Indexed keywords

ADJUVANT; CHLAMYDIA TRACHOMATIS RECOMBINANT MAJOR OUTER MEMBRANE PROTEIN; CPG 1826; FLAGELLIN; GAMMA INTERFERON; IMIQUIMOD; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; LIPOPEPTIDE; MURAMYL DIPEPTIDE; NEISSERIA GONORRHOEAE RECOMBINANT PORIN B; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; OUTER MEMBRANE PROTEIN; PAM2CSK4 ADJUVANT; PHOSPHORYL LIPID A; POLYINOSINIC POLYCYTIDYLIC ACID; RECOMBINANT PROTEIN; RESIQUIMOD; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELLULAR IMMUNITY; CHLAMYDIA TRACHOMATIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; LIGAND BINDING; LUNG WEIGHT; LYMPHOCYTE PROLIFERATION; MOUSE; NEISSERIA GONORRHOEAE; NONHUMAN; NUCLEOTIDE SEQUENCE; PNEUMONIA; PRIORITY JOURNAL; TH2 CELL; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; BODY WEIGHT; BRONCHOPNEUMONIA; CELL PROLIFERATION; CHLAMYDIA INFECTIONS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LUNG; MICE; PORINS; RECEPTORS, IMMUNOLOGIC; RODENT DISEASES; VACCINATION;

EID: 80051664904     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.105     Document Type: Article

References (72)

1. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124(February (4)):783-801.
2. Lemaitre B., Nicolas E., Michaut L., Reichhart J.M., Hoffmann J.A. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996, 86(September (6)):973-983.
3. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4(July (7)):499-511.
4. Rock F.L., Hardiman G., Timans J.C., Kastelein R.A., Bazan J.F. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA 1998, 95(January (2)):588-593.
5. Xu D., Liu H., Komai-Koma M. Direct and indirect role of Toll-like receptors in T cell mediated immunity. Cell Mol Immunol 2004, 1(August (4)):239-246.
6. Schnare M., Barton G.M., Holt A.C., Takeda K., Akira S., Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001, 2(October (10)):947-950.
7. Centers for Disease Control and Prevention (CDC) Chlamydia screening among sexually active young female enrollees of health plans-United States, 2000-2007. MMWR Morb Mortal Wkly Rep 2009, 58(April (14)):362-365.
8. Schachter J., Dawson C. Human chlamydial infections 1978, PSG Publishing Co., Littleton.
9. Miller W.C., Ford C.A., Morris M., Handcock M.S., Schmitz J.L., Hobbs M.M., et al. Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA 2004, 291(May (18)):2229-2236.
10. Stamm W. Chlamydia trachomatis infections of the adult 2008, McGrawHill Book Co., New York, p. 575-93.
11. Gotz H., Lindback J., Ripa T., Arneborn M., Ramsted K., Ekdahl K. Is the increase in notifications of Chlamydia trachomatis infections in Sweden the result of changes in prevalence, sampling frequency or diagnostic methods?. Scand J Infect Dis 2002, 34(1):28-34.
12. Brunham R.C., Pourbohloul B., Mak S., White R., Rekart M.L. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. J Infect Dis 2005, 192(November (10)):1836-1844.
13. de la Maza L.M., Peterson E.M. Vaccines for Chlamydia trachomatis infections. Curr Opin Investig Drugs 2002, 3(July (7)):980-986.
14. Brunham R.C., Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat Rev Immunol 2005, 5(February (2)):149-161.
15. Rockey D.D., Wang J., Lei L., Zhong G. Chlamydia vaccine candidates and tools for chlamydial antigen discovery. Expert Rev Vaccines 2009, 8(October (10)):1365-1377.
16. de la Maza M.A., de la Maza L.M. A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections. Vaccine 1995, 13(January (1)):119-127.
17. Morrison R.P., Caldwell H.D. Immunity to murine chlamydial genital infection. Infect Immun 2002, 70(June (6)):2741-2751.
18. Igietseme J.U., Ramsey K.H., Magee D.M., Williams D.M., Kincy T.J., Rank R.G. Resolution of murine chlamydial genital infection by the adoptive transfer of a biovar-specific, Th1 lymphocyte clone. Reg Immunol 1993, 5(November-December (6)):317-324.
19. Igietseme J.U., Magee D.M., Williams D.M., Rank R.G. Role for CD8+ T cells in antichlamydial immunity defined by Chlamydia-specific T-lymphocyte clones. Infect Immun 1994, 62(November (11)):5195-5197.
20. Perry L.L., Feilzer K., Caldwell H.D. Immunity to Chlamydia trachomatis is mediated by T helper 1 cells through IFN-gamma-dependent and -independent pathways. J Immunol 1997, 158(April (7)):3344-3352.
21. Cheng C., Cruz-Fisher M.I., Tifrea D., Pal S., Wizel B., de la Maza L.M. Induction of protection in mice against a respiratory challenge by a vaccine formulated with the Chlamydia major outer membrane protein adjuvanted with IC31((R)). Vaccine 2011, 29(March (13)):2437-2443.
22. Cheng C., Bettahi I., Cruz-Fisher M.I., Pal S., Jain P., Jia Z., et al. Induction of protective immunity by vaccination against Chlamydia trachomatis using the major outer membrane protein adjuvanted with CpG oligodeoxynucleotide coupled to the nontoxic B subunit of cholera toxin. Vaccine 2009, 27(October (44)):6239-6246.
23. Pal S., Peterson E.M., de la Maza L.M. Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect Immun 2005, 73(December (12)):8153-8160.
24. Kari L., Whitmire W.M., Crane D.D., Reveneau N., Carlson J.H., Goheen M.M., et al. Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine. J Immunol 2009, 182(June (12)):8063-8070.
25. Caldwell H.D., Kromhout J., Schachter J. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect Immun 1981, 31(March (3)):1161-1176.
26. Sun G., Pal S., Weiland J., Peterson E.M., de la Maza L.M. Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein. Vaccine 2009, 27(August (36)):5020-5025.
27. Marston F.A. The purification of eukaryotic polypeptides synthesized in Escherichia coli. Biochem J 1986, 240(November (1)):1-12.
28. Blake M.S., Gotschlich E.C. Purification and partial characterization of the opacity-associated proteins of Neisseria gonorrhoeae. J Exp Med 1984, 159(February (2)):452-462.
29. Qi H.L., Tai J.Y., Blake M.S. Expression of large amounts of neisserial porin proteins in Escherichia coli and refolding of the proteins into native trimers. Infect Immun 1994, 62(June (6)):2432-2439.
30. Schagger H., von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100kDa. Anal Biochem 1987, 166(November (2)):368-379.
31. Ezoe H., Akeda Y., Piao Z., Aoshi T., Koyama S., Tanimoto T., et al. Intranasal vaccination with pneumococcal surface protein A plus poly(I:C) protects against secondary pneumococcal pneumonia in mice. Vaccine 2011, 29(February (9)):1754-1761.
32. Didierlaurent A.M., Morel S., Lockman L., Giannini S.L., Bisteau M., Carlsen H., et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009, 183(November (10)):6186-6197.
33. Skountzou I., Martin Mdel P., Wang B., Ye L., Koutsonanos D., Weldon W., et al. Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 2010, 28(May (24)):4103-4112.
34. Wilson-Welder J.H., Torres M.P., Kipper M.J., Mallapragada S.K., Wannemuehler M.J., Narasimhan B. Vaccine adjuvants: current challenges and future approaches. J Pharm Sci 2009, 98(April (4)):1278-1316.
35. Hui G.S., Hashimoto C.N. Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment. Int Immunopharmacol 2008, 8(July (7)):1012-1022.
36. Pal S., Fielder T.J., Peterson E.M., de la Maza L.M. Protection against infertility in a BALB/c mouse salpingitis model by intranasal immunization with the mouse pneumonitis biovar of Chlamydia trachomatis. Infect Immun 1994, 62(August (8)):3354-3362.
37. Pal S., Davis H.L., Peterson E.M., de la Maza L.M. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge. Infect Immun 2002, 70(September (9)):4812-4817.
38. Quadros C. Preventing disease and protecting health 2004, Pan American Health Organization, Washington.
39. Plotkin S.A. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008, 47(August (3)):401-409.
40. Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007, 13(May (5)):552-559.
41. Blander J.M., Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006, 440(April (7085)):808-812.
42. Trinchieri G., Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007, 7(March (3)):179-190.
43. Levine M.M. New generation vaccines 2010, Informa Healthcare USA, New York. 4th ed.
44. Plotkin S.A., Orenstein W.A., Offit P.A. Vaccines 2008, Saunders/Elsevier, Philadelphia, PA. 5th ed.
45. Harandi A.M., Davies G., Olesen O.F. Vaccine adjuvants: scientific challenges and strategic initiatives. Expert Rev Vaccines 2009, 8(March (3)):293-298.
46. Holmgren J., Czerkinsky C., Eriksson K., Mharandi A. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 2003, 21(June (Suppl. 2)):S89-S95.
47. Mastelic B., Ahmed S., Egan W.M., Del Giudice G., Golding H., Gust I., et al. Mode of action of adjuvants: implications for vaccine safety and design. Biologicals 2010, 38(September (5)):594-601.
48. Bas S., Neff L., Vuillet M., Spenato U., Seya T., Matsumoto M., et al. The proinflammatory cytokine response to Chlamydia trachomatis elementary bodies in human macrophages is partly mediated by a lipoprotein, the macrophage infectivity potentiator, through TLR2/TLR1/TLR6 and CD14. J Immunol 2008, 180(January (2)):1158-1168.
49. Welter-Stahl L., Ojcius D.M., Viala J., Girardin S., Liu W., Delarbre C., et al. Stimulation of the cytosolic receptor for peptidoglycan, Nod1, by infection with Chlamydia trachomatis or Chlamydia muridarum. Cell Microbiol 2006, 8(June (6)):1047-1057.
50. O'Connell C.M., AbdelRahman Y.M., Green E., Darville H.K., Saira K., Smith B., et al. Toll-like receptor 2 activation by Chlamydia trachomatis is plasmid dependent, and plasmid-responsive chromosomal loci are coordinately regulated in response to glucose limitation by C. trachomatis but not by C. muridarum. Infect Immun 2011, 79(March (3)):1044-1056.
51. O'Connell C.M., Ingalls R.R., Andrews C.W., Scurlock A.M., Darville T. Plasmid-deficient Chlamydia muridarum fail to induce immune pathology and protect against oviduct disease. J Immunol 2007, 179(September (6)):4027-4034.
52. Ingalls R.R., Rice P.A., Qureshi N., Takayama K., Lin J.S., Golenbock D.T. The inflammatory cytokine response to Chlamydia trachomatis infection is endotoxin mediated. Infect Immun 1995, 63(August (8)):3125-3130.
53. Derbigny W.A., Kerr M.S., Johnson R.M. Pattern recognition molecules activated by Chlamydia muridarum infection of cloned murine oviduct epithelial cell lines. J Immunol 2005, 175(November (9)):6065-6075.
54. Joyee A.G., Yang X. Role of toll-like receptors in immune responses to chlamydial infections. Curr Pharm Des 2008, 14(6):593-600.
55. Prebeck S., Kirschning C., Durr S., da Costa C., Donath B., Brand K., et al. Predominant role of toll-like receptor 2 versus 4 in Chlamydia pneumoniae-induced activation of dendritic cells. J Immunol 2001, 167(September (6)):3316-3323.
56. Neff L., Daher S., Muzzin P., Spenato U., Gulacar F., Gabay C., et al. Molecular characterization and subcellular localization of macrophage infectivity potentiator, a Chlamydia trachomatis lipoprotein. J Bacteriol 2007, 189(July (13)):4739-4748.
57. Kimbrell M.R., Warshakoon H., Cromer J.R., Malladi S., Hood J.D., Balakrishna R., et al. Comparison of the immunostimulatory and proinflammatory activities of candidate Gram-positive endotoxins, lipoteichoic acid, peptidoglycan, and lipopeptides, in murine and human cells. Immunol Lett 2008, 118(June (2)):132-141.
58. Schmidt J., Welsch T., Jager D., Muhlradt P.F., Buchler M.W., Marten A. Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase I/II trial. Br J Cancer 2007, 97(September (5)):598-604.
59. Wu W., Li R., Malladi S.S., Warshakoon H.J., Kimbrell M.R., Amolins M.W., et al. Structure-activity relationships in toll-like receptor-2 agonistic diacylthioglycerol lipopeptides. J Med Chem 2010, 53(April (8)):3198-3213.
60. Buwitt-Beckmann U., Heine H., Wiesmuller K.H., Jung G., Brock R., Akira S., et al. Toll-like receptor 6-independent signaling by diacylated lipopeptides. Eur J Immunol 2005, 35(January (1)):282-289.
61. Buwitt-Beckmann U., Heine H., Wiesmuller K.H., Jung G., Brock R., Akira S., et al. TLR1- and TLR6-independent recognition of bacterial lipopeptides. J Biol Chem 2006, 281(April (14)):9049-9057.
62. Becker P.D., Fiorentini S., Link C., Tosti G., Ebensen T., Caruso A., et al. The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant. Vaccine 2006, 24(June (25)):5269-5276.
63. Borsutzky S., Ebensen T., Link C., Becker P.D., Fiorelli V., Cafaro A., et al. Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. Vaccine 2006, 24(March (12)):2049-2056.
64. Liang Y., Hasturk H., Elliot J., Noronha A., Liu X., Wetzler L.M., et al. Toll-like receptor 2 induces mucosal homing receptor expression and IgA production by human B cells. Clin Immunol 2011, 138(January (1)):33-40.
65. Brunham R.C., Kuo C.C., Cles L., Holmes K.K. Correlation of host immune response with quantitative recovery of Chlamydia trachomatis from the human endocervix. Infect Immun 1983, 39(March (3)):1491-1494.
66. Pal S., Theodor I., Peterson E.M., de la Maza L.M. Monoclonal immunoglobulin A antibody to the major outer membrane protein of the Chlamydia trachomatis mouse pneumonitis biovar protects mice against a chlamydial genital challenge. Vaccine 1997, 15(April (5)):575-582.
67. Zhong G.M., Peterson E.M., Czarniecki C.W., Schreiber R.D., de la Maza L.M. Role of endogenous gamma interferon in host defense against Chlamydia trachomatis infections. Infect Immun 1989, 57(January (1)):152-157.
68. Zhong G.M., Peterson E.M., Czarniecki C.W., de la Maza L.M. Recombinant murine gamma interferon inhibits Chlamydia trachomatis serovar L1 in vivo. Infect Immun 1988, 56(January (1)):283-286.
69. Darville T., O'Neill J.M., Andrews C.W., Nagarajan U.M., Stahl L., Ojcius D.M. Toll-like receptor-2, but not Toll-like receptor-4, is essential for development of oviduct pathology in chlamydial genital tract infection. J Immunol 2003, 171(December (11)):6187-6197.
70. Karimi O., Ouburg S., de Vries H.J., Pena A.S., Pleijster J., Land J.A., et al. TLR2 haplotypes in the susceptibility to and severity of Chlamydia trachomatis infections in Dutch women. Drugs Today (Barc) 2009, 45(November (Suppl. B)):67-74.
71. Cazorla S.I., Becker P.D., Frank F.M., Ebensen T., Sartori M.J., Corral R.S., et al. Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi. Infect Immun 2008, 76(January (1)):324-333.
72. Bafica A., Scanga C.A., Feng C.G., Leifer C., Cheever A., Sher A. TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J Exp Med 2005, 202(December (12)):1715-1724.